

PROGRAMAÇÃO CIENTÍFICA

17/06/2016 | Sexta-Feira

Horário	Módulo	Aula	Palestrante
Coordenadores: Paulo Marcelo Gehm Hoff (SP) e Caio Max S. Rocha Lima (USA)			
16:00 17:00	1. Gastrintestinal - Câncer Colorretal (1)	Abstract ID: 3504 Title: Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance)	Gustavo dos Santos Fernandes (DF)
		Abstract: 3503 Title: NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA)	Gabriel Prolla (RS)
		Abstract ID: 3512 Title: FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – accord 21 (METHEP-2), a unicancer GI trial	Rui Fernando Weschenfelder (RS)
		Abstract ID: 3511 Title: The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers	Fernando Meton de Alencar Camara Vieira (RJ)
		Abstract ID: 3507 Title: CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer—Results of the UK Colo Rectal Endoscopic Stenting Trial (CREST)	
		Discussão	
Coordenadores: Sergio Jobim de Azevedo (RS) e Mohammad Jahanzeb (USA)			
17:00 18:00	2. Câncer de Mama (1)	Abstract ID: 1007 Title: Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance)	Márcio Debiasi (RS)
		Abstract ID: 1005 (170268) Title: A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01)	
		Abstract ID: LBA503 Title: Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin	Pedro Henrique Araújo de Souza (SP)
		Abstract ID: 512 Title: Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA)	Marcelo Rocha de Sousa Cruz (SP)
		Abstract ID: 507 Title: PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).	Tomás Reinert (RS)
		Discussão	
Coordenador: Artur Katz (SP)			
18:00 19:00	3. Cancer de Pulmão (1)	Abstract ID: 8504 (165387) Title: CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS)	Luiz Henrique de Lima Araujo (RJ)
		Abstract ID: 9008 Title: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study	Clarissa Seródio da Rocha Baldotto (RJ)
		Abstract ID: 108 Title: Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)	
		Abstract ID: 8507 Title: E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets	Clarissa Maria de Cerqueira Mathias (BA)
		Discussão	
19:00 20:00	Simpósio Satélite: AstraZeneca		

PROGRAMAÇÃO CIENTÍFICA

18/06/2016 | Sábado

Horário	Módulo	Aula	Palestrante
Coordenador: Fernando Cotait Maluf (SP)			
08:00 09:00	4. Câncer Geniturinário	Abstract: 5006 Title: Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA)	Daniel Herchenhorn (RJ)
		Abstract: 5008 Title: Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D)	
		Abstract: 5001 Title: A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high-risk prostate cancer: Results of SPCG12	André Poisl Fay (RS)
		Abstract: 5003 Title: A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer	
		Abstract: 4506 Title: Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC)	
		Abstract: LBA4500 Title: Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1	
		Discussão	
Coordenador: Aknar Freire de Carvalho Calabrich (BA)			
09:00 10:00	5. Câncer Ginecológico	Abstract ID: 5508 Title: Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS)	Angélica Nogueira Rodrigues (MG)
		Abstract ID: LBA5503 Title: OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)	Andréia Cristina de Melo (RJ)
		Abstract ID: 5501 Title: Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis	Maria Del Pilar Estevez Diz (SP)
		Discussão	
Coordenador: Jacques Tabacof (SP)			
10:00 11:00	6. Câncer de Pulmão (2)	Abstract ID: 9012 Title: A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study	Jacques Tabacof (SP)
		Abstract ID: 9004 Title: Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study	Igor A. Protzner Morbeck (DF)
		Abstract ID: 100 Title: Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC)	Vladmir Cláudio Cordeiro de Lima (SP)
		Abstract ID: 3001 Title: CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC	
		Discussão	
Horário	Módulo	Aula	Palestrante
Coordenadores: Carlos H. Barrios (RS) e Mohammad Jahanzeb (USA)			
11:00 12:00	7. Câncer de Mama (2)	Abstract ID: 500 Title: Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)	Pedro Liedke (RS)
		Abstract ID: 1000 (166500) Title: Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer	Ricardo José Marques (SP)
		Abstract ID: LBA1 Title: A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer	Pedro Liedke (RS)
		Discussão	

12:00 12:30	Intervalo		
Coordenadores: Anelisa K. Coutinho (BA) e Caio Max S. Rocha Lima (USA)			
12:30 13:30	8. Gastrointestinal (2)	Abstract: 4003 Title: Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance)	Jorge Sabagga (SP)
		Abstract: 4005 Title: NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE	Rachel Riechelman (SP)
		Abstract: LBA4006 Title: ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.	Duílio Reis da Rocha Filho (CE)
		Abstract: 4000 Title: A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study	Maria de Lourdes Lopes de Oliveira (RJ)
		Abstract: LBA4001 Title: FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma	
Discussão			
Coordenador: Antonio Carlos Buzaid (SP)			
13:30 14:30	9. Melanoma	Abstract ID: 9503 (167363) Title: Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001	Antonio Carlos Buzaid (SP)
		Abstract ID: 9504 Title: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006	
		Abstract ID: 9505 Title: Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067)	Sergio Jobim de Azevedo (RS)
		Abstract ID: 9506 (167092) Title: Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort	
		Abstract ID: 9502 Title: Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma	
Discussão			
Coordenadores: Carlos H. Barrios (RS) e Carlos Sampaio (BA)			Participantes
14:30 15:30	Painel	Colocando as Apresentações no Contexto Atual: O que muda na Prática Clínica	Caio Max S. Rocha Lima (USA) Mohammad Jahanzeb (USA) Antonio Carlos Buzaid (SP) Jacques Tabacof (SP) Fernando Cotait Maluf (SP) Aknar Freire de Carvalho Calabrich (BA)
15:30	Encerramento		

PACOTE DE VIAGEM

APROVEITEM NOSSAS TARIFAS ESPECIAIS PARA O CONGRESSO!

A reserva de hotel é *on-line*.

VAGAS LIMITADAS!

PARA FAZER SUA RESERVA, ACESSE:

www.eventusturismo.com.br

HOSPEDAGEM - 02 noites

Entrada: 17/06/2016 | Saída: 19/06/2016

HOTEL	SINGLE	DOUBLE
TIVOLI	R\$ 1.600,00	R\$ 1.874,00

*Os preços incluem **02 diárias** com café da manhã, almoço e jantar.

FORMA DE PAGAMENTO: BOLETO BANCÁRIO*

***Atenção: O boleto bancário terá o vencimento para 05 dias a contar da data da reserva.**

CASO DESEJE UMA MAIOR PERMANÊNCIA, CONSULTE-NOS.

OBSERVAÇÕES IMPORTANTES:

- ❖ As diárias começam às 15:00h e encerram às 12:00h do dia seguinte.
- ❖ Não reembolsamos em casos de cancelamento, redução ou desistência.
- ❖ Os preços não incluem bebidas, telefonemas interurbanos, taxas de inscrições no Congresso e demais despesas de caráter pessoal. Não incluem transfer aeroporto/hotel/aeroporto, porém na compra do pacote de hospedagem e passagem aérea, o valor do transfer será especial.
- ❖ A **Eventus Turismo Ltda.**, EMBRATUR 00721-00-42-8, opera como intermediária entre o passageiro, a cia. aérea e o hotel, não assumindo desta forma nenhuma responsabilidade por erros, falhas, extravios ou atrasos de qualquer uma das empresas envolvidas. Em caso de doenças, os gastos correrão por conta do passageiro.

PASSAGEM AÉREA:

A Eventus Turismo, por ser a agência de viagens oficial do evento, possui um desconto adicional nas tarifas divulgadas pela TAM.

Assim, no momento da emissão da passagem, nosso cliente terá até 25% a mais de desconto na tarifa apresentada no sistema da CIA AÉREA.

NOSSOS CONTATOS

EVENTUS TURISMO LTDA
Tel: (5571) 2104.3420 / Fax:(5571) 2104.3427
e-mail: turismo@eventusturismo.com.br

